Loading...
2014 has been a year of transition for NEJM Journal Watch AIDS Clinical Care. Early in the year, after a decade at the helm, Dr. Paul Sax moved on to become editor-in-chief of the new Infectious Diseases Society of America journal Open Forum Infectious Diseases. In July, we were incorporated into NEJM Journal Watch Infectious Diseases. Meanwhile, science was advancing, and new discoveries were being made. It has been very difficult to come up with five “top stories” from among the many HIV/AIDS-related articles we have reviewed for NEJM Journal Watch in 2014. You may consider others more worthy, so please forgive me if I have not included your favorites.
The chosen stories cover the disappointing results from two patients who experienced viral rebound when antiretroviral therapy (ART) was stopped after allogeneic stem-cell transplantation, despite the seeming absence of HIV before ART discontinuation; ART combinations for initial therapy (inclusion of nucleosides for patients with CD4 counts <200 cells/mm3 and a comparison of three recommended efavirenz-free regimens); deferral of ART initiation in patients with cryptococcal meningitis; and possible underestimation of the need for statins in HIV-infected individuals.
Our HIV/AIDS Top Stories of 2014 are:
An NRTI-Sparing Regimen for HIV-Infected, Treatment-Naive Patients?
Comparison of the “Other” Regimens for HIV-Naive Patients
When Should ART Be Started in HIV-Infected Patients with Cryptococcal Meningitis?
Cholesterol Guidelines May Underestimate Cardiovascular Risk in HIV-Infected Patients